Biogen and Neomorph have entered a research partnership aimed at discovering and developing molecular glue degraders for the treatment of Alzheimer’s disease and other neurological and immunological conditions. The partnership will leverage Neomorph’s molecular glue discovery platform to detect and validate new small molecule therapeutic molecular glue degraders. The gold standard of business intelligence.
Neomorph CEO, co-founder and president Phil Chamberlain stated: “Neomorph’s molecular glue degrader platform represents a unique approach to drug discovery. “We are excited to partner with Biogen, a leader in Alzheimer’s, rare and immunological diseases, to explore the potential of our technology in addressing some of the most challenging and valuable targets in these fields.” The parties will work together to detect, validate and streamline small molecule molecular glue degraders for high-priority targets.
Biogen will be responsible for advancing the clinical candidates for further development and subsequent commercialisation. Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research.
Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form Neomorph will receive an upfront payment and mi.
